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INTRODUCTION
Resistance against Mycobacterium tuberculosis (MTB) is
important in the sense that it has an implication in the
control of tuberculosis. The terms used to describe
resistance to anti-tuberculosis drugs are resistance
among new cases (or primary resistance) and
resistance among previously treated patients.1 The
resistance among previously treated patients may be
due to faulty treatment like prescription of inadequate
treatment regimens, interrupted availability or poor
quality of drugs, or incomplete treatment adherence2
while subsequent transmission of these resistant
organisms to others will lead to development of disease
which is resistant from the beginning called primary
resistance.3
Pakistan is ranked eighth in terms of global estimated
burden of tuberculosis cases. Multi-Drug Resistant
(MDR) tuberculosis among new cases and MDR among
previously treated patients is 3.2% and 35% respectively.4
There are small studies on resistance pattern from
Pakistan. 
The objective of this study was to retrospectively
determine the resistance pattern against both first and
second line drugs in MDR-TB patients during a decade
at a specialized tuberculosis treatment centre.
METHODOLOGY
It is a retrospective observational study conducted at
MDR ward of Ojha Institute of Chest Diseases (OICD).
The microbiological records of 577 culture proven cases
of MDR pulmonary tuberculosis patients registered at
OICD from 1996 to 2006 were reviewed. The patients
were labeled as MDR- TB if their sputum culture and
sensitivity report show resistance against both
Rifampicin (R) and INH. All the study patients had a
previous history of TB and use of anti-TB drugs so all
the cases had secondary MDR-TB excluded. All those
isolates sensitivity against either Rifampicin or INH were
excluded. All patients were admitted initially followed by
treatment in the clinic of the Institute. 
Ethical Review Committee of Ojha Institute of Chest
Diseases, Karachi, approved the study.
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All sputum specimens were processed at Microbiology
Department, the Aga Khan University Hospital, Karachi.
The sputum were digested and decontaminated using
the N-acetyl-Lcysteine-NaOH method, as recommended
by Centres for Disease Control and Prevention (CDC).5,6
Specimens were concentrated using centrifugation
(3000 x g) for 30 minutes and sediment was used for
AFB microscopy and culture. 
Sputum smears were prepared and screened by
Auramine Rhodamine fluorochrome staining. The
positive slides were then confirmed by Kinyoun
modification of Ziehl Neelson stain. Isolation of Mycobacterium
tuberculosis (MTB) was performed using standard
methodology.7
The specimens were inoculated on both liquid and solid
media i.e. MGIT and Lowenstein Jensen (LJ) medium.
For LJ slant 0·1 ml of concentrated specimen were
inoculated and incubated for 8 weeks. MGIT vials were
inoculated with 0·5 ml of specimen and incubated at
37oC after supplementation of medium with OADC and
PANTA. Growth from the positive LJ slant and MGIT
vials were first stained with Kinyoun and M. tuberculosis
was identified by BACTEC NAP TB differentiation test,
growth in PNB containing media, nitrate reduction and
niacin accumulation.7
Susceptibility testing was performed using Agar
proportion method on enriched Middle Brook 7H10
medium (BBL) at the following concentrations; Rifampicin
1ug/ml and 5 ug/ml, Isoniazid 0·2 ug/ml and 1ug/ml,
Streptomycin 2 ug/ml and 10 ug/ml, Ethambutol 5 ug/ml
and 10 ug/ml, Ethionamide 5 ug/ml, Capreomycin 10
ug/ml, Cycloserine 30 ug/ml and Ciprofloxacin 2 ug/ml.8
Pyrazinamide sensitivity was carried out using the
BACTEC 7H12 medium pH 6·0 at 100 µg/ml. During the
study period MTB H37Rv was used as control with each
batch of susceptibility testing.
Only resistance to the higher concentration were used
for analysis to ensure selection of high level resistance
strains. Isoniazid resistance was defined as resistance to
the higher concentrations (1 ug/ml) of the drug. Rifampicin
resistance was defined as resistance to the higher
concentrations (5 ug/ml) of the drug. Streptomycin
resistance was defined as resistance to the higher
concentrations (10 ug/ml) of the drug. Ethambutol
resistance was defined as resistance to the higher
concentrations (10 ug/ml) of the drug. 
At the time of study, AKL was not checking sensitivities
against Amikacin and Kanamycin and only tested four
classes of second line TB drugs-Ethionamide, Capreo-
mycin, Cycloserine and Ciprofloxacin/Ofloxacin. Therefore,
all MDR TB isolates resistant to Ciprofloxacin and
Capreomycin were taken as extensively drug resistant
tuberculosis (XDR-TB). 
MDR was defined as resistance to at least Isoniazid and
Rifampicin. Five drug resistant MTB was resistant to all
five first line drugs including INH, Rifampicin, Pyrazinamide,
Ethambutol and Streptomycin. 
Extensively drug resistant tuberculosis (XDR-TB) was
defined as resistance to any Quinolone and to one of the
injectable second line drugs in addition to MDR. 
The statistical package for social science SPSS (release
11.0.5) was used to analyze the data. Descriptive
analysis was done for demographic, clinical and
laboratory data. The results were presented as mean
with standard deviation (SD) and numbers (percentages).
RESULTS
During the study period, a total of 577 MDR-TB patients
were enrolled. There were 345 (59.7%) males. The
mean age was 32.44±12.64 years. All the patients had
received more than one course of anti-tuberculosis
treatment (ATT) in the past. All the patients belonged to
low socioeconomic status. Resistance to both INH and
Rifampicin i.e. MDR tuberculosis was seen in all
patients. Resistance against other first line drugs were
76.60% for Pyrazinamide, 73% for Ethambutol  and
68.11% for Streptomycin. Resistant pattern against first
and second line ATT is presented in Figures 1 and 2.
Three hundred twenty six (56.5%) were resistant to all
five first line drugs, while 510 (88%) were MDR plus
resistant to one more first line drug. Resistant pattern
against different combinations of drugs are presented in
Table I.
Forty (07%) isolates were MDR plus resistant to
Quinolone. They were not tested against Amikacin or
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Figure 1: Resistance pattern of
Mycobacterium tuberculosis against first
line drugs.
Figure 2: Resistance pattern of
Mycobacterium tuberculosis against 2nd
line drugs.
PZA: Pyrazinamide, Etham: Ethambutol, 
Strept: Streptomycin
Oflo: Ofloxacin, Cyclo: Cycloserine, Ethion:
Ethionamide, Capre: Capreomycin
Table I:  Resistance pattern of MTB in MDR patients.
Antituberculous drugs Resistance  N (%)
MDR+ one more 1st line drug 510 (88%)
Resistant to all 5 first line drugs 326 (56.5%)
MDR + Quino 40 (7%)
Resistant to 5 first line drugs + Quino 06 (1.03%)
Resistance to different combinations of first line drugs






MTB: Mycobacterium tuberculosis;   MDR: Multidrug resistance;   R: Rifampicin;   H: Isoniazid;
Z: Pyrazinamide;   E: Ethambutol;   S: Streptomycin;   Quino: Quinolone.
Kanamycin, however, they were found to be sensitive to
Capreomycin. Six (1.03%) isolates were resistant to all
five first line drugs plus Quinolone.
DISCUSSION
This is the first large study on resistance pattern against
first and second line anti-tuberculosis treatment (ATT)
agents in MDR-TB patients. Previously published
national and international studies were mainly focused
on the primary and acquired drug resistance against first
line antituberculous drugs in various group of patients.
In this study, the focus was on the resistant pattern of
first and second line ATT among MDR patients.
Very high resistance against all five first line drugs was
noted as 56.5% in this study, which suggest faulty
treatment in the past. In a global survey conducted by
World Health Organization and International Union
against tuberculosis and lung disease in 35 countries in
five subcontinents resistance to 4 first line drugs
(excluding Streptomycin) among previously treated
patients was 0-17% with median of 4.4%.9 The median
prevalence of acquired MDR tuberculosis was 13%, with
a range of 0% (Kenya) to 54% (Latvia).9 Data from the
recent survey from 66 countries and two Specially
Administered Areas (SARs) of China in previously
treated patients show highest proportions of MDR-TB  in
Baku City, Azerbaijan (55.8%) and Tashkent, Uzbekistan
(60.0%) while data from India show 17.2%.10
Resistance to TB drugs has been widely reported from
various parts of the country.11-17 Study done by Irfan
et al.18 reported  35.2% of their MDR isolates were
resistant to all five first line antituberculous agents. They
showed an overall resistance rate of 64% to the
antituberculous drugs. Other studies reported 36-73%
resistance rates in different groups of patients.11-17
Karamat et al., had reported single-drug resistance
among Mycobacterium tuberculosis from both pulmonary and
extra-pulmonary isolates at 21%, multi-drug resistance at
14% and resistance to all four first-line drugs at 5% in
Rawalpindi-Islamabad.14 The incidence of MDR was
reported in local data from 21 to 24%.11,15,17
The very high resistance for all first line drugs is likely
because only those cases were selected that were MDR
and had a history of previous anti-TB treatment.
Resistance against second line drugs in this cohort of
patients were low (1.2-2.5%) except for Quinolones
(7.3%). So far, no data is available against the sensitivity
of second line drugs in Pakistan, so these results remain
unique. Even a low resistance rate of second line drugs
is alarming for the treatment of this group of patients and
will in lead to more XDR cases.  
Forty (07%) isolates were MDR plus resistant to
Quinolone with questionable XDR tuberculosis. The
Quinolones are being used for large number of pulmonary
indications like pneumonia, chronic bronchitis exacer-
bation, sinusitis etc. and over use of any single agent will
ultimately result in resistance to the entire class.19
Quinolone have been found very effective in the
management of drug-resistant tuberculosis.20 
All the patients had received multiple courses of anti-
tuberculosis treatment (ATT) mostly from their general
practitioners (GPs) and use of Quinolone is quite high
among GPs of Pakistan. Most of the patients admitted
that they would stop treatment at their own once they
feel better. The detail treatment record was not available
in almost all the patients. Studies have shown that there
is a direct association between previous TB treatment
and an increased prevalence of drug resistance.18,21 To
decrease resistance, adequate and complete therapy for
patients diagnosed with tuberculosis should be ensured. 
In Pakistan, 80% of the TB patients initially report to their
general practitioners.23 and involvement of GPs is
crucial for effective TB control. They need to be
sensitized and trained by organizing workshops, as
most of them neither follow National Tuberculosis
Control Program (NTP) guidelines nor practice Directly
Observed Treatment Short course (DOTS). The problem
of drug resistance can be overcome by DOTS strategy.
It is said that effective TB control program leads to
decrease in resistance pattern.24 The Pakistan TB
control program is working on achieving the WHO
recommended target of 70% case detection and 85%
treatment success rate. WHO’s recent report (Ref-S)
state that the case detection rate in Pakistan is
increasing and is just below target at 67%, while the
treatment success rate has reached 88%. The report
correlates this increase with public-private mix (PPM)
initiatives.
All the patients belonged to low socioeconomic status.
Masroor and Ziaullah reported that low socioeconomic
status is associated with increase number of drug
resistant cases.22,25
There are certain limitations of this study; first, this study
was done in a tertiary care referral TB centre so the very
high resistance rate were expected and so these results
cannot be  generalized results for the whole community.
Second, there were no result of second line drugs
resistance in all cases so the resistance against second
line drugs may be underestimated. Third, there is no
data against Kanamycin and Amikacin so the
prevalence of XDR in this cohort of cases could not be
estimated.
CONCLUSION
High resistance rates in MDR-TB to remaining first line
and second line drugs was found. Continuous
monitoring and regular surveillance of drug resistance
pattern especially of MDR isolates and treatment in
specialized centres is a crucial need for future TB
control in Pakistan.
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